CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer.

Abstract

CYFRA 21-1 is a new tumor marker using two different monoclonal antibodies which recognize the divergent epitope on the N- or C-terminal region of domain 2 of cytokeratin 19 fragment, respectively. In this study, we investigated the relationship between levels of CYFRA 21-1 and survival duration, as well as the efficacy of chemotherapy associated with changes in CYFRA 21-1. Serum samples were obtained from 87 patients with nonoperable lung cancer (35 cases with squamous-cell carcinoma, 33 with adenocarcinoma, 3 with large-cell carcinoma, and 16 with small-cell carcinoma). The cutoff point was set at 3.5 ng/ml. In a CYFRA 21-1 assay, significantly more patients with squamous-cell carcinoma and adenocarcinoma were positive compared to patients with small-cell and large-cell carcinomas (p = 0.0017). Following chemotherapy, blood levels of CYFRA 21-1 decreased significantly in responders versus nonresponders (p = 0.0246). A significant correlation was noted between survival periods and pretreatment levels of CYFRA 21-1 (p = 0.0036). The present study suggests that CYFRA 21-1 might be useful as a possible indicator of survival and therapeutic effect for lung cancer.

• Authors: Y Takei, K Minato, S Tsuchiya, A Takise, H Nakano, K Ezawa, N Fueki, H Hoshino, I Naruse, T Nomoto, T Makimoto, S Ishihara, R Saito, M Mori
• Journal: Oncology (Oncology) 1997 Jan-Feb Vol. 54 Issue 1 Pg. 43-7 ISSN: 0030-2414 [Print] Switzerland
• PMID: 8978592 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• Biomarkers, Tumor
• Keratin-19
• antigen CYFRA21.1
• Keratins

Topics

• Aged
• Antigens, Neoplasm (blood)
• Biomarkers, Tumor (blood)
• Carcinoma (immunology, therapy)
• Female
• Humans
• Keratin-19
• Keratins
• Lung Neoplasms (immunology, therapy)
• Male
• Middle Aged
• Predictive Value of Tests
• Survival Analysis
• Treatment Outcome